Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Asimadoline (TP0052), a Peripherally Restricted Selective Kappa Agonist, for the Treatment of Moderate to Severe Menopausal Symptoms in Midlife Women.

NCT07042516 is registered in ClinicalTrials.gov with Tioga Pharmaceuticals as lead sponsor.

NCT NCT07042516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07042516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Asimadoline (TP0052), a Peripherally Restricted Selective Kappa Agonist, for the Treatment of Moderate to Severe Menopausal Symptoms in Midlife Women.
Lead sponsor
Tioga Pharmaceuticals
Phase
Phase 2
Overall status
Recruiting
Start date
August 13, 2025
Completion date
December 31, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vasomotor symptoms